TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $185,818 | -41.5% | 20,785 | +0.5% | 0.00% | -100.0% |
| Q2 2023 | $317,722 | -26.6% | 20,685 | +7.5% | 0.00% | 0.0% |
| Q1 2023 | $432,595 | +6.9% | 19,235 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $404,512 | -33.1% | 19,235 | -21.7% | 0.00% | -50.0% |
| Q3 2022 | $605,000 | +1.7% | 24,555 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $595,000 | -6.0% | 24,555 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $633,000 | -16.9% | 24,555 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $762,000 | +25.5% | 24,555 | -1.9% | 0.00% | 0.0% |
| Q3 2021 | $607,000 | +66.3% | 25,038 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $365,000 | -35.7% | 25,038 | +10.0% | 0.00% | 0.0% |
| Q1 2021 | $568,000 | -76.9% | 22,765 | -74.7% | 0.00% | -80.0% |
| Q4 2020 | $2,455,000 | – | 90,065 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,028,875 | $25,351,000 | 8.34% |
| GREAT POINT PARTNERS LLC | 966,108 | $23,805,000 | 5.73% |
| Deep Track Capital, LP | 4,000,000 | $98,560,000 | 4.51% |
| RA Capital Management | 4,922,941 | $121,301,000 | 2.59% |
| ARMISTICE CAPITAL, LLC | 5,836,000 | $143,799,000 | 2.49% |
| Kynam Capital Management, LP | 416,729 | $10,268,000 | 2.16% |
| MPM BioImpact LLC | 276,460 | $6,812,000 | 1.61% |
| HighVista Strategies LLC | 110,698 | $2,728,000 | 1.56% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 186,019 | $4,582,000 | 1.47% |
| SECTORAL ASSET MANAGEMENT INC | 249,700 | $6,153,000 | 1.21% |